CMV-specific T cell therapy.
Human cytomegalovirus (CMV) infection continues to be one of the most important and life threatening complications after allogeneic stem cell transplantation (SCT). The reconstitution of CMV-specific T cell responses after SCT has been demonstrated to be protective against the development of CMV disease. To improve T cell immunity against CMV in bone marrow transplant patients, different strategies were explored. On one hand, CMV-specific T cells can be selected from the donor, and can be transferred to the patient without any further in vitro expansion. On the other hand, CMV-specific T cells can be activated and expanded in vitro by stimulation with antigen presenting cells (APCs) loaded with specific proteins or peptides. Here, we review the therapeutic application of CMV-specific T cells to fight CMV infection.
Einsele
Hermann
H
Medizinische Klinik und Poliklinik II, Julius Maximilians University of Würzburg, Germany.
Kapp
Markus
M
Grigoleit
Götz Ulrich
GU
D019264:Adoptive Transfer / Q000379:methods*; D000956:Antigens, Viral / Q000276:immunology / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000628:therapy*; D006801:Humans; D017710:Lymphocyte Transfusion; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology / Q000637:transplantation*
D000956:Antigens, Viral